The discovery of Dorzagliatin,a novel glucokinase activator was a potential game changer for Type 2 Diabetes treatment. Over the last few year’s China’s HUA Medicine has taken the drug through clinical trials onto the market for T2D patients in China. But to understand how and why this works we have to look at its role in Glucose Homeostasis. Long sought after, but for many years neglected by the research community, glucose homeostasis describes the delicate balancing act the body plays in managing glucose levels - and which goes so wrong in diabetes patients. Supported by clinicians across China, and with data published in global journals including the Lancet and Nature, HUA Medicine believes Dorzagliatin holds the promise to restore glucose homeostasis, and provide hope for patients not just in China, but around the world.
www.huamedicin...
21 июн 2023
